洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

L 洛斯公司

未开盘 04-14 16:00:00 EDT

110.28

+0.05

+0.05%

盘后110.21

-0.07-0.07%

19:46 EDT

最高110.66	最低108.95	成交量67.60万
今开109.53	昨收110.23	日振幅1.55%
总市值227.90亿	流通市值187.64亿	总股本2.07亿
成交额7,453万	换手率0.40%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"L","market":"US","secType":"STK","nameCN":"洛斯公司","latestPrice":110.28,"timestamp":1776196800000,"preClose":110.23,"halted":0,"volume":676001,"hourTrading":{"tag":"盘后","latestPrice":110.205025,"preClose":110.28,"latestTime":"19:46 EDT","volume":70386,"amount":7762149.182025,"timestamp":1776210399215,"change":-0.074975,"changeRate":-0.00068,"amplitude":0.00068},"delay":0,"changeRate":0.0004535970244034941,"floatShares":170151602,"shares":206659567,"eps":7.972262,"marketStatus":"未开盘","change":0.05,"latestTime":"04-14 16:00:00 EDT","open":109.53,"high":110.655,"low":108.95,"amount":74529265.73023,"amplitude":0.015468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.972262,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776240000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":-341002800000,"exchange":"NYSE","adjPreClose":110.23,"dividendRate":0.002267,"preHourTrading":{"tag":"盘前","latestPrice":110.6,"preClose":110.23,"latestTime":"09:29 EDT","volume":72,"amount":7897.060079999999,"timestamp":1776173347518,"change":0.37,"changeRate":0.003357,"amplitude":0.017509},"postHourTrading":{"tag":"盘后","latestPrice":110.205025,"preClose":110.28,"latestTime":"19:46 EDT","volume":70386,"amount":7762149.182025,"timestamp":1776210399215,"change":-0.074975,"changeRate":-0.00068,"amplitude":0.00068},"volumeRatio":1.084811,"impliedVol":0.2552,"impliedVolPercentile":0.864},"requestUrl":"/m/hq/s/L","defaultTab":"news","newsList":[{"id":"2624521056","title":"上海市市监局：50批次冲锋衣抽检不合格4批次，涉海格拉夫火柴棍等品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2624521056","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624521056?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:16","pubTimestamp":1775099790,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月2日讯，近日，上海市市场监管局对浦东、青浦、长宁等8个区23家企业销售的50批次冲锋衣开展监督抽查，检出4批次不合格，不合格率为8.0%。监管部门已责令相关经营者立即停止销售、全面清理库存及在售产品，并将案件移送属地市场监管部门依法查处。同时提醒消费者选购时注意查看产品标签、外观工艺及气味，按说明规范洗涤保养，以保障防水功能持久有效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775097903631221376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["M","BK4588","BK4107","LU0053666078.USD","BK4103","L","LU0210528500.USD","BK4585","LU2487616109.SGD","BK4220"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624601597","title":"营收同比下降33.8%，基石药业押注三抗管线进展如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624601597","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624601597?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:50","pubTimestamp":1775040648,"startTime":"0","endTime":"0","summary":"继2024年上半年首次实现盈利、全年财务业绩持续改善后，基石药业（2616.HK）2025年业绩再度下滑。年报显示，公司2025年实现收入2.7亿元，同比下降33.8%；年内亏损扩大至4.37亿元，较2024年的0.91亿元亏损增加3.46亿元。在业绩承压的背景下，基石药业同步披露了PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新开发进展及I/II期关键临床数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692073178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692073178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4107","BK4588","LU0053666078.USD","BK4585","ORR","L","LU0210528500.USD","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114590532","title":"Spire以2.15亿美元将天然气营销业务出售给Boardwalk Pipelines","url":"https://stock-news.laohu8.com/highlight/detail?id=1114590532","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114590532?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:59","pubTimestamp":1774879191,"startTime":"0","endTime":"0","summary":"Spire公司宣布，已达成协议将其天然气营销业务出售给Boardwalk Pipelines，交易金额为2.15亿美元。此次资产剥离是Spire优化业务组合、聚焦核心业务战略的一部分。与此同时，Spire公司表示正在评估其天然气储存设施的出售可能性，预计将在2026财年第二季度前提供最新进展。在财务指引方面，Spire公司预计2027财年调整后每股收益将在5.40美元至5.60美元之间，较此前预期的5.65美元至5.85美元有所下调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU2362541513.USD","LU1621767737.EUR","LU1621768206.USD","BK4107","LU0053666078.USD","IE000M9KFDE8.USD","LU2463526074.USD","LU2362541273.HKD","LU1621767810.EUR","BK4081","LU2384288077.EUR","IE00B29SXK94.USD","LU1244550221.USD","BK4566","IE00B29SXL02.USD","LU1430594728.SGD","LU1244550577.SGD","BK4588","LU1244550494.USD","BK4585","DUK","LU1585245621.USD","L","LU1621768115.EUR","LU2487616109.SGD","LU0210528500.USD","BK4606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191166730","title":"Chubb与DFC合作公布海湾海事保险机制具体架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1191166730","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191166730?lang=zh_cn&edition=full","pubTime":"2026-03-21 01:57","pubTimestamp":1774029449,"startTime":"0","endTime":"0","summary":"3月20日——Chubb有限公司披露了与美国国际开发金融公司（DFC）合作设立的海湾海事保险机制的具体架构。根据安排，DFC将负责协调美国再保险公司联盟并设定承保资格标准。\n该海湾海事保险机制旨在为船舶船体、责任险及货物提供战争海上风险保险。在符合特定条件的情况下，通过霍尔木兹海峡的船只可申请获得此项保险服务。\n（来源时间：2026年3月20日17:45:37 GMT）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","LU2487616109.SGD","L","BK4588","LU0053666078.USD","BK4107","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132811598","title":"Pyxis Oncology宣布临时CEO任命及领导层交接，聚焦战略重点与项目延续性","url":"https://stock-news.laohu8.com/highlight/detail?id=1132811598","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132811598?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:49","pubTimestamp":1770119377,"startTime":"0","endTime":"0","summary":"波士顿，2026年2月3日——临床阶段生物制药公司Pyxis Oncology, Inc.今日宣布领导层交接计划，旨在持续推进公司战略与临床目标的执行。自公司首次公开募股以来一直担任董事会成员的Thomas Civik被任命为临时首席执行官，即刻生效。通过此次人事调整，Pyxis Oncology将由深度熟悉公司战略及研发项目的资深领导者掌舵。董事会主席John Flavin表示：\"任命Tom为临时CEO是为了确保领导力的稳健过渡与业务连续性。Pyxis Oncology已奠定坚实的科研与临床基础，我们对核心项目的前景保持乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4022","L","LU0053666078.USD","LU0210528500.USD","BK4231","LU2487616109.SGD","BK4232","BK4139","BK4080","R","BK4107","PYXS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601793498","title":"超20亿美元交易官宣终止，宜明昂科：对下一步BD充满信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2601793498","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601793498?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:39","pubTimestamp":1767778775,"startTime":"0","endTime":"0","summary":"“坦率讲，我个人对目前把全球权益拿回来是感到非常高兴的。”在1月7日早上的电话会上，宜明昂科生物医药技术（上海）股份有限公司（宜明昂科，1541.HK）创始人、董事长田文志表达了上述感受。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601073611555858.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611555858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU0210528500.USD","BK4588","LU0053666078.USD","BK4107","LU2487616109.SGD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600089095","title":"达伯舒新适应症医保落地 系晚期pMMR子宫内膜癌唯一医保抗PD-(L)1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600089095","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600089095?lang=zh_cn&edition=full","pubTime":"2026-01-01 15:16","pubTimestamp":1767251765,"startTime":"0","endTime":"0","summary":"中国网财经1月1日讯今日，北京、上海、苏州、郑州等多地医院开出信迪利单抗注射液(达伯舒)新增子宫内膜癌适应症医保处方，标志着该适应症在被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》后正式落地执行医保价格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601013607458241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601013607458241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4107","L","LU2487616109.SGD","PD","BK4023","BK4585","LU1169589451.USD","LU1169590202.USD","LU0210528500.USD","BK4588","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123923184","title":"洛斯公司 - 最高法院发现与基础合伙协议相关的违约行为，发回审理侵权干扰问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1123923184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123923184?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457296,"startTime":"0","endTime":"0","summary":"洛斯公司 - 最高法院发现与基础合伙协议相关的违约行为，发回审理侵权干扰问题","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","L","LU0053666078.USD","LU0210528500.USD","BK4588","BK4585","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590394122?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4588","BK4006","ADC","BK4107","LU2065731478.USD","CRS","L","IE00B7SZL793.SGD","LU0963586101.USD","IE0031619046.USD","BK4187","LU0053666078.USD","BK4231","IE00B19Z4B17.USD","LU0210528500.USD","IE00B66KJ199.SGD","LU2487616109.SGD","BK4585","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586225792","title":"三生制药：707联合化疗的临床2期数据公布 即将开展两项关键3期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2586225792","media":"国信证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586225792?lang=zh_cn&edition=full","pubTime":"2025-11-27 07:57","pubTimestamp":1764201420,"startTime":"0","endTime":"0","summary":"近日，三生制药在2025 年STIC 会议上以LBA 方式发布707 联合化疗在一线NSCLC 的临床2 期研究数据。辉瑞与三生制药达成协议后，积极推进707 的临床开发，并将707 管线列为其核心管线，目前已经提交5 个新的临床申请，在全球超过25 个城市、500 多家临床中心开展临床研究，预计到2026 年底将新增10 个适应症的临床试验，以及10 个以上的新型治疗方案。辉瑞即将在NSCLC 和CRC 适应症中开展两项临床3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127091749951c9fe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127091749951c9fe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0170899867.USD","L","LU0306806265.USD","LU1883839398.USD","IE00BLSP4452.SGD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","LU0122379950.USD","LU2487616109.SGD","LU0225771236.USD","SG9999003800.SGD","LU1894683264.USD","SGXZ57979304.SGD","BK4588","BK4533","LU0289739699.SGD","SG9999002232.USD","BK4534","BK4581","BK4585","LU0058720904.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU0210528500.USD","SG9999013999.USD","IE00BBT3K403.USD","LU0225284248.USD","LU1066051498.USD","BK4107","LU0321505868.SGD","LU1894683348.USD","LU0456855351.SGD","LU0234572021.USD","IE0002270589.USD","SG9999001176.SGD","SG9999002224.SGD","SG9999011175.SGD","LU1057294990.SGD","BK4599","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0306807586.USD","BK4007","IE000M9KFDE8.USD","BK4550","BK4568","LU0053666078.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1159433604","title":"CNA金融第三季度调整后每股收益为1.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159433604","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159433604?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:28","pubTimestamp":1763569705,"startTime":"0","endTime":"0","summary":"11月3日 - CNA金融第三季度每股收益为1.48美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4588","BK4107","L","LU2487616109.SGD","BK4585","LU0210528500.USD","CNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125354250","title":"洛斯公司选举迪诺·罗布斯托为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1125354250","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125354250?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:27","pubTimestamp":1763569679,"startTime":"0","endTime":"0","summary":"11月3日 - 洛斯公司（Loews）宣布，迪诺·罗布斯托（Dino Robusto）被选为其董事会成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["L","LU0053666078.USD","LU0210528500.USD","LU2487616109.SGD","BK4107","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583584449","title":"新股消息 | 明基医院更新招股书 为华东地区最大的民营营利性综合医院集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584449","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583584449?lang=zh_cn&edition=full","pubTime":"2025-11-13 07:32","pubTimestamp":1762990322,"startTime":"0","endTime":"0","summary":"招股书显示，明基医院是中国内地的一家民营营利性综合医院集团，目前该公司拥有和运营南京明基医院和苏州明基医院等两家民营营利性综合医院。根据弗若斯特沙利文的数据，以2024年总收入计，南京明基医院是中国第三大民营营利性综合医院，亦是江苏省最大的民营营利性综合医院。苏州明基医院2013年开始运营，为三级综合性医院。明基医院专注于通过公司的多学科民营营利性综合医院为患者提供连续的优质医疗服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["L","BK4588","LU0053666078.USD","LU0154236417.USD","09906","LU1978683503.SGD","LU1854103824.USD","LU0070302665.USD","LU0320765489.SGD","LU1989764748.USD","BK4107","IE00B894F039.SGD","JCI","BK4585","IE00B3T34201.USD","LU1854104046.USD","LU1989764664.SGD","BK4504","LU0210528500.USD","IE00BZ9MQY76.HKD","LU2487616109.SGD","02581","LU0211331839.USD","LU0124384867.USD","BK1209","LU0312595415.SGD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0208291251.USD","BK4580","BK4086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582034364","title":"药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2582034364","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582034364?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:29","pubTimestamp":1762918190,"startTime":"0","endTime":"0","summary":"【药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响】凭借在肺癌领域的突出表现，默沙东的PD-1单抗K药连续在2023年、2024年成为全球药王，年销售额均突破200亿美元。谁能成为肺癌领域下一代免疫“新王”，一场争夺赛在药企中已打响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511123562061651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511123562061651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1720050803.USD","LU2488822045.USD","01801","BK1574","LU2097828714.EUR","L","09926","LU0417516571.SGD","02696","LU0417516738.SGD","LU1794554557.SGD","LU2487616109.SGD","LU2476274720.SGD","BK1589","BK4588","LU0502904849.HKD","LU2328871848.SGD","BK1161","HK0000165453.HKD","LU1969619763.USD","LU2097828805.USD","BK4585","LU2242644610.SGD","LU0455707207.USD","LU0210528500.USD","LU1961090484.USD","LU0348766576.USD","LU0348827113.USD","LU0634319403.HKD","IE00BPRC5H50.USD","BK4107","LU2097828557.USD","LU0348735423.USD","LU0348825331.USD","LU0417516902.SGD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU2778985437.USD","LU2476274308.USD","IE00B543WZ88.USD","LU0348783233.USD","BK1583","LU2097828474.EUR","LU0348767384.USD","LU2399975544.HKD","LU0348784397.USD","LU0053666078.USD","LU0561508036.HKD","ORR","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149794522","title":"CNA金融2023年第三季度调整后每股收益为1.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149794522","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149794522?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:15","pubTimestamp":1762168530,"startTime":"0","endTime":"0","summary":"11月3日 - CNA金融第三季度每股收益为1.48美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0210528500.USD","BK4107","BK4585","L","CNA","LU2487616109.SGD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577367573","title":"PD-(L)1/VEGF赛道攻坚，依沃西冲击首个海外适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367573","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577367573?lang=zh_cn&edition=full","pubTime":"2025-10-22 11:58","pubTimestamp":1761105514,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明当地时间10月20日，SummitTherapeutics（纳斯达克股票代码：SMMT）在2025年三季度财报中宣布，将于2025年第四季度向美国食品药品监督管理局（FDA）提交依沃西单抗联合化疗的生物制品许可申请（BLA），用于治疗经第三代EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌（NSCLC）患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510223540978275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540978275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["L","BK4585","BK4588","LU0053666078.USD","LU0210528500.USD","LU2487616109.SGD","LU1169589451.USD","PD","BK4107","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511921636","title":"洛斯公司2024财年实现净利润14.14亿美元，同比减少1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511921636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511921636?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:00","pubTimestamp":1739548828,"startTime":"0","endTime":"0","summary":"2月15日，洛斯公司公布财报，公告显示公司2024财年净利润为14.14亿美元，同比减少1.39%；其中营业收入为175.10亿美元，同比增加10.44%，每股基本收益为6.42美元。从资产负债表来看，洛斯公司总负债579.55亿美元，其中短期债务70.00百万美元，资产负债比为1.31，流动比率为0.60。机构评级：截至2025年2月15日，当前有1家机构对洛斯公司目标价做出预测，其中目标均价为82.00美元，其中最低目标价为82.00美元，最高目标价为82.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000036abcf1ab3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000036abcf1ab3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168620937","title":"Loews第四季度每股收益同比下降至$0.86，销售额同比上升至$45.5亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1168620937","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168620937?lang=zh_cn&edition=full","pubTime":"2025-02-10 19:02","pubTimestamp":1739185368,"startTime":"0","endTime":"0","summary":"Loews报告其季度每股收益为$0.86。这较去年同期的每股收益$1.99下降了56.78%。公司本季度报告的销售额为$45.5亿，较去年同期的$42.6亿增长了6.76%。以上内容来自Benzinga Earnings专栏，原文如下：Loews  reported quarterly earnings of $0.86 per share. This is a 56.78 percent decrease over earnings of $1.99 per share from the same period last year.  The company reported $4.55 billion in sales this quarter. This is a 6.76 percent increase over sales of $4.26 billion the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Loews第四季度每股收益同比下降至$0.86，销售额同比上升至$45.5亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161193077","title":"港股期权｜腾讯期权交投多空焦灼，一Put单半日成交逾万张；快手看多情绪高涨！一Call单飙涨500%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161193077","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161193077?lang=zh_cn&edition=full","pubTime":"2025-02-05 12:41","pubTimestamp":1738730495,"startTime":"0","endTime":"0","summary":"$TCH.HK 20250328 410.00 PUT$ 快手看多情绪高涨，一Call单飙涨500%！","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1aa932a22cd44cca9770ee6b16021b1b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01024","IE0031814852.USD","HSTECH","TCEHY","BK1591","LU1794554557.SGD","BK1502","BK1531","BK1590","00700","IE00B8L5B284.USD","IE00BGV7N243.SGD","YANG","IE00B97KM107.HKD","KSTmain","IE00B5MMRT66.SGD","LU1719994722.HKD","L","HSCEI","07226","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.loews.com","stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.0645},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.2776},{"period":"ytd","weight":0.0472}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"美国洛斯保险公司是一家成立于1969年的控股公司，旗下拥有从事多种业务运营的子公司。其主要子公司包括提供商业财产和意外伤害保险的CNA Financial Corporation；涉足天然气、天然气液体和其他碳氢化合物的运输和储存的木板路管线，LP；以及经营连锁酒店的洛斯保险酒店控股公司。此外，洛斯保险还拥有Altium Packaging LLC的权益，该公司是一家硬质塑料包装解决方案制造商。该公司通过四个部门报告其财务业绩：CNA Financial Corporation、木板路管线 Pipeline Partners、LP、洛斯保险 Hotels Holding Corporation以及企业部门。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.007002},{"month":2,"riseRate":0.565217,"avgChangeRate":0.005501},{"month":3,"riseRate":0.586957,"avgChangeRate":-0.006832},{"month":4,"riseRate":0.617021,"avgChangeRate":0.007395},{"month":5,"riseRate":0.565217,"avgChangeRate":0.021104},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.001635},{"month":7,"riseRate":0.521739,"avgChangeRate":-0.001249},{"month":8,"riseRate":0.521739,"avgChangeRate":0.017827},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00607},{"month":10,"riseRate":0.673913,"avgChangeRate":0.012707},{"month":11,"riseRate":0.608696,"avgChangeRate":0.024712},{"month":12,"riseRate":0.652174,"avgChangeRate":0.020518}],"exchange":"NYSE","name":"洛斯公司","nameEN":"Loews"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供洛斯公司(L)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"洛斯公司,L,洛斯公司股票,洛斯公司股票老虎,洛斯公司股票老虎国际,洛斯公司行情,洛斯公司股票行情,洛斯公司股价,洛斯公司股市,洛斯公司股票价格,洛斯公司股票交易,洛斯公司股票购买,洛斯公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供洛斯公司(L)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}